RxDoctor Payments Data

David Garza, MD

Internal Medicine · Plano, TXNPI 1043380306

Payments from drug & device makers

$8,022in general payments, 2019–2025

Across 486 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$654
  • Amarin Pharma, Inc.$565
  • Boehringer Ingelheim$552
  • Lilly USA, LLC$490
  • Johnson & Johnson$453
  • plus $4K from 52 others

What the payments were for

  • Food & beverage$7,95699%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,022 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$156,842
Medicare patients
207
Services billed
4,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$65,428
JardianceEmpagliflozin41$62,511
JanuviaSitagliptin Phosphate38$47,389
MounjaroTirzepatide25$37,449
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$20,112
JanumetSitagliptin Phos/Metformin Hcl11$17,613
VascepaIcosapent Ethyl19$13,251
ArexvyRsvpref3 Antigen/As01e/Pf24$7,447
BelsomraSuvorexant11$6,373
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$5,773
Rosuvastatin Calcium273$4,330
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,265
SynthroidLevothyroxine Sodium31$2,188
Ezetimibe88$2,107
Olmesartan Medoxomil70$1,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Belsomra$374$71,37560 claims
Novo NordiskOzempic$654$65,42849 claims
Boehringer IngelheimJardiance$552$62,51141 claims
Lilly USA, LLCMounjaro$490$37,44925 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$413$30,82459 claims
AbbVieSynthroid$1,004$2,18831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →